News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
700,112 Results
Type
Article (39861)
Company Profile (249)
Press Release (660002)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (204279)
Career Advice (2016)
Deals (35459)
Drug Delivery (95)
Drug Development (81067)
Employer Resources (172)
FDA (16193)
Job Trends (14905)
News (345380)
Policy (32563)
Tag
Academia (2556)
Accelerated approval (5)
Adcomms (20)
Allergies (86)
Alliances (49449)
ALS (95)
Alzheimer's disease (1383)
Antibody-drug conjugate (ADC) (132)
Approvals (16190)
Artificial intelligence (261)
Autoimmune disease (22)
Automation (17)
Bankruptcy (360)
Best Places to Work (11677)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (175)
Bladder cancer (79)
Brain cancer (27)
Breast cancer (290)
Cancer (2311)
Cardiovascular disease (179)
Career advice (1682)
Career pathing (30)
CAR-T (154)
Cell therapy (434)
Cervical cancer (20)
Clinical research (66087)
Collaboration (854)
Company closure (2)
Compensation (565)
Complete response letters (19)
COVID-19 (2590)
CRISPR (41)
C-suite (250)
Cystic fibrosis (101)
Data (2315)
Decentralized trials (2)
Denatured (19)
Depression (44)
Diabetes (275)
Diagnostics (6379)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (102)
Drug shortages (25)
Duchenne muscular dystrophy (96)
Earnings (87029)
Editorial (39)
Employer branding (21)
Employer resources (146)
Events (112686)
Executive appointments (737)
FDA (17563)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (765)
Gene editing (109)
Generative AI (19)
Gene therapy (311)
GLP-1 (717)
Government (4431)
Grass and pollen (4)
Guidances (156)
Healthcare (18822)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (122)
Indications (29)
Infectious disease (2735)
Inflammatory bowel disease (143)
Inflation Reduction Act (8)
Influenza (52)
Intellectual property (98)
Interviews (314)
IPO (16524)
IRA (40)
Job creations (3638)
Job search strategy (1427)
Kidney cancer (10)
Labor market (43)
Layoffs (475)
Leadership (17)
Legal (7922)
Liver cancer (76)
Lung cancer (324)
Lymphoma (157)
Machine learning (9)
Management (58)
Manufacturing (323)
MASH (76)
Medical device (13384)
Medtech (13389)
Mergers & acquisitions (19503)
Metabolic disorders (706)
Multiple sclerosis (83)
NASH (16)
Neurodegenerative disease (93)
Neuropsychiatric disorders (27)
Neuroscience (1934)
NextGen: Class of 2025 (6518)
Non-profit (4482)
Now hiring (40)
Obesity (371)
Opinion (206)
Ovarian cancer (80)
Pain (91)
Pancreatic cancer (88)
Parkinson's disease (150)
Partnered (21)
Patents (242)
Patient recruitment (115)
Peanut (46)
People (57377)
Pharmaceutical (64)
Pharmacy benefit managers (19)
Phase I (20584)
Phase II (29111)
Phase III (21678)
Pipeline (1356)
Policy (147)
Postmarket research (2563)
Preclinical (8757)
Press Release (64)
Prostate cancer (107)
Psychedelics (30)
Radiopharmaceuticals (247)
Rare diseases (383)
Real estate (5910)
Recruiting (65)
Regulatory (22328)
Reports (47)
Research institute (2321)
Resumes & cover letters (350)
Rett syndrome (6)
RNA editing (5)
RSV (42)
Schizophrenia (70)
Series A (131)
Series B (87)
Service/supplier (11)
Sickle cell disease (52)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3587)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (48)
The Weekly (30)
Vaccines (697)
Venture capitalists (42)
Weight loss (237)
Women's health (36)
Worklife (16)
Date
Today (61)
Last 7 days (962)
Last 30 days (2991)
Last 365 days (32408)
2025 (11729)
2024 (35234)
2023 (40095)
2022 (51191)
2021 (55733)
2020 (54098)
2019 (46556)
2018 (35042)
2017 (32150)
2016 (31525)
2015 (37573)
2014 (31331)
2013 (26348)
2012 (28577)
2011 (29266)
2010 (27329)
Location
Africa (722)
Alabama (54)
Alaska (7)
Arizona (233)
Arkansas (13)
Asia (37903)
Australia (6195)
California (6380)
Canada (2060)
China (535)
Colorado (271)
Connecticut (278)
Delaware (157)
Europe (81443)
Florida (950)
Georgia (213)
Idaho (57)
Illinois (553)
India (25)
Indiana (320)
Iowa (11)
Japan (171)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (918)
Massachusetts (4736)
Michigan (224)
Minnesota (402)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (67)
New Hampshire (63)
New Jersey (1785)
New Mexico (28)
New York (1797)
North Carolina (985)
North Dakota (8)
Northern California (2811)
Ohio (208)
Oklahoma (14)
Oregon (34)
Pennsylvania (1421)
Puerto Rico (13)
Rhode Island (33)
South America (1101)
South Carolina (25)
South Dakota (1)
Southern California (2401)
Tennessee (105)
Texas (946)
United States (23904)
Utah (188)
Virginia (151)
Washington D.C. (65)
Washington State (562)
West Virginia (3)
Wisconsin (56)
700,112 Results for "allergan inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025
March 24, 2025
·
10 min read
Press Releases
Allergan Aesthetics unveils new AA Signature Program and immersive booth at IMCAS World Congress 2025
January 24, 2025
·
10 min read
Press Releases
Allergan Aesthetics launches new AA Signature Program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans
January 29, 2025
·
7 min read
Business
Allergan Aesthetics and University Lab Partners Announce the Golden Ticket Pitch Competition to Accelerate Aesthetics Start-Ups
University Lab Partners (ULP) is thrilled to announce the return of the Golden Ticket pitch competition for aesthetic startups, proudly sponsored by Allergan Aesthetics, an AbbVie Company.
April 12, 2024
·
2 min read
Infectious disease
AbbVie Gets FDA Approval for New Antibiotic in the Face of Rising Resistance
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in partnership with Pfizer. AbbVie acquired its share of the asset as part of its $63 billion buyout of Allergan.
February 10, 2025
·
2 min read
·
Dan Samorodnitsky
Business
AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios
AbbVie and Allergan Aesthetics, an AbbVie company, today announced they will present 29 abstracts, including three late-breaking presentations, during the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12, in San Diego, California.
March 6, 2024
·
34 min read
Press Releases
Rubedo Life Sciences Appoints Former Allergan Executive and Biotechnology Veteran Dr. Frederick Beddingfield III as CEO
November 11, 2024
·
3 min read
Drug Development
Allergan Aesthetics Launches BOTOX® Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in China
September 11, 2024
·
13 min read
Press Releases
Allergan Aesthetics to Present New Data at 2024 American Society for Dermatologic Surgery (ASDS) to Showcase Depth Across Facial Aesthetics and Insight into Patient Perception
October 17, 2024
·
7 min read
Drug Development
Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced positive topline results from two pivotal Phase 3 clinical studies evaluating trenibotulinumtoxinE (BoNT/E) for the treatment of moderate to severe glabellar lines (M21-500 and M21-508).
October 24, 2023
·
4 min read
1 of 70,012
Next
